Ronald W. Bohl, Senior director supply chain, Eli Lilly about Eli Lilly's Synchronized Lean Production

Ronald W. Bohl, Senior director supply chain, Eli Lilly
Ronald W. Bohl, Senior director supply chain, Eli Lilly

"It is not about improving the accuracy of the forecast and reducing the amount of uncertainty in the future, it is about eliminating the need for certainty."
Ronald W. Bohl, Senior director supply chain, Eli Lilly

Eli Lilly adopted a supply chain excellence initiative in order to reduce costs and meet changing market requirements. To reduce the need for certainty in supply chain planning and efficiently synchronize production and distribution, the company introduced four Lean SCM concepts to its supply chains: aggregate forecasts, pull-control using VMI, postponement strategies, and Rhythm Wheels for production planning and scheduling. These innovations enabled them to substantially reduce lead and cycle times as well as inventories along the supply chain. Furthermore, such supply chain optimization reduced the need to invest in costly new resources.

Learn more about Lean Supply Chain Planning, just visit www.leansupplychainplanning.com.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.